Description

PT-141 (Bremelanotide) Dosage Protocol

PT-141 is a synthetic peptide derived from Melanotan II, designed to activate melanocortin receptors (primarily MC3R and MC4R) in the central nervous system. Unlike PDE5 inhibitors, PT-141 works independently of nitric oxide pathways, directly influencing sexual arousal, libido, and erectile response in both men and women. It does not significantly impact hormone levels such as testosterone or IGF-1.

Clinical studies have demonstrated PT-141’s effectiveness in treating hypoactive sexual desire disorder (HSDD) and erectile dysfunction, with a well-characterized safety profile when used within recommended ranges.

This educational protocol outlines an as-needed subcutaneous approach with precise dosing calculations.

Reconstitute:
Add 2.0 mL bacteriostatic water → ~5 mg/mL (5000 mcg/mL) concentration (based on a 10 mg vial)

Typical Usage:

Start: 500 mcg (0.5 mg) as needed
Common range: 500–1000 mcg (0.5–1 mg)
Maximum: Up to 1.5 mg per dose
Frequency: No more than 1 dose per 24 hours, 2–3 times per week max
Administer 30–60 minutes before activity

Easy Measuring:
At 5 mg/mL,

1 unit = 0.01 mL ≈ 50 mcg on a U-100 insulin syringe

Example:

500 mcg dose ≈ 10 units
1 mg dose ≈ 20 units
1.5 mg dose ≈ 30 units

Administration:

Subcutaneous injection (abdomen or thigh)
Rotate injection sites to minimize irritation

Storage:

Lyophilized: Store at −20 °C (−4 °F)
After reconstitution: Refrigerate at 2–8 °C (35.6–46.4 °F)
Protect from light and avoid repeated freeze–thaw cycles

Note:
PT-141 is commonly researched for its effects on libido enhancement, sexual performance, and arousal disorders. Some users may experience mild side effects such as nausea, flushing, or temporary increased blood pressure, especially at higher doses.